<table id="t3" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3	Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction<footnote>This table is not all inclusive.</footnote>
</caption>
<col align="left" valign="top" width="33%"></col>
<col align="left" valign="top" width="27%"></col>
<col align="left" valign="top" width="40%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule" valign="middle">Concomitant Drug Class: Drug Name</th>
<th align="center" stylecode="Rrule" valign="middle">Effect on Concentration<footnote>↓ = decrease, ↑ = increase</footnote>
</th>
<th align="center" stylecode="Rrule" valign="middle">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Acid Reducing Agents:</content>
</td>
<td rowspan="4" stylecode="Rrule">↓ ledipasvir</td>
<td stylecode="Rrule">Ledipasvir solubility decreases as pH increases. Drugs that increase gastric pH are expected to decrease concentration of ledipasvir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Antacids (e.g., aluminum and magnesium hydroxide)</td>
<td stylecode="Rrule">It is recommended to separate antacid and HARVONI administration by 4 hours.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">H<sub>2</sub>-receptor antagonists<footnote id="ft2">These interactions have been studied in healthy adults.</footnote> (e.g., famotidine)<br/>
</td>
<td stylecode="Rrule">H<sub>2</sub>-receptor antagonists may be administered simultaneously with or 12 hours apart from HARVONI at a dose that does not exceed doses comparable to famotidine 40 mg twice daily.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Proton-pump inhibitors<footnoteref idref="ft2"></footnoteref> (e.g., omeprazole)</td>
<td stylecode="Rrule">Proton-pump inhibitor doses comparable to omeprazole 20 mg or lower can be administered simultaneously with HARVONI under fasted conditions.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antiarrhythmics:</content>
<br/>amiodarone</td>
<td stylecode="Rrule">Effect on amiodarone, ledipasvir, and sofosbuvir concentrations unknown</td>
<td stylecode="Rrule">Coadministration of amiodarone with HARVONI may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. Coadministration of amiodarone with HARVONI is not recommended; if coadministration is required, cardiac monitoring is recommended <content stylecode="italics">[see <linkhtml href="#S5.1">Warnings and Precautions (5.1)</linkhtml>, <linkhtml href="#S6.2">Adverse Reactions (6.2)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">												digoxin</td>
<td stylecode="Rrule">↑ digoxin</td>
<td stylecode="Rrule">Coadministration of HARVONI with digoxin may increase the concentration of digoxin. Therapeutic concentration monitoring of digoxin is recommended when coadministered with HARVONI.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants:</content>
<br/>carbamazepine      <br/>phenytoin              <br/>phenobarbital  <br/>     oxcarbazepine</td>
<td stylecode="Rrule">↓ ledipasvir<br/>↓ sofosbuvir<br/>↓ GS-331007</td>
<td stylecode="Rrule">Coadministration of HARVONI with carbamazepine, phenytoin, phenobarbital, or oxcarbazepine is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of HARVONI. Coadministration is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterials:</content>
<br/>rifabutin   <br/>rifampin<footnoteref idref="ft2"></footnoteref>
<br/> rifapentine</td>
<td stylecode="Rrule">↓ ledipasvir<br/>↓ sofosbuvir<br/>↓ GS-331007</td>
<td stylecode="Rrule">Coadministration of HARVONI with rifabutin or rifapentine is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of HARVONI. Coadministration is not recommended.<br/>Coadministration of HARVONI with rifampin, a P-gp inducer, is not recommended <content stylecode="italics">[see <linkhtml href="#S5.2">Warnings and Precautions (5.2)</linkhtml>].</content>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV Antiretrovirals:</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">efavirenz,        <br/>emtricitabine,        <br/>tenofovir disoproxil fumarate (DF)</td>
<td stylecode="Rrule">↑ tenofovir</td>
<td stylecode="Rrule">Monitor for tenofovir-associated adverse reactions in patients receiving HARVONI concomitantly with the combination of efavirenz, emtricitabine and tenofovir DF. Refer to VIREAD, TRUVADA, or ATRIPLA prescribing information for recommendations on renal monitoring.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Regimens containing tenofovir DF and a HIV protease inhibitor/ritonavir 											<list>
<item>atazanavir/ritonavir + emtricitabine/tenofovir DF<footnoteref idref="ft2"></footnoteref>
</item>
<item>darunavir/ritonavir + emtricitabine/tenofovir DF<footnoteref idref="ft2"></footnoteref>
</item>
<item>lopinavir/ritonavir + emtricitabine/tenofovir DF</item>
</list>
</td>
<td stylecode="Rrule">↑ tenofovir</td>
<td stylecode="Rrule">The safety of increased tenofovir concentrations in the setting of HARVONI and a HIV protease inhibitor/ritonavir has not been established.<br/>Consider alternative HCV or antiretroviral therapy to avoid increases in tenofovir exposures. If coadministration is necessary, monitor for tenofovir-associated adverse reactions. Refer to VIREAD or TRUVADA prescribing information for recommendations on renal monitoring.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">elvitegravir, cobicistat, emtricitabine, tenofovir DF</td>
<td stylecode="Rrule">↑ tenofovir</td>
<td stylecode="Rrule">The safety of increased tenofovir concentrations in the setting of HARVONI and the combination of elvitegravir, cobicistat, emtricitabine and tenofovir DF has not been established. Coadministration is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">tipranavir/ritonavir</td>
<td stylecode="Rrule">↓ ledipasvir<br/>↓ sofosbuvir<br/>↓ GS-331007</td>
<td stylecode="Rrule">Coadministration of HARVONI with tipranavir/ritonavir is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of HARVONI. Coadministration is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HCV Products:</content>
<br/>simeprevir<footnoteref idref="ft2"></footnoteref>
</td>
<td stylecode="Rrule">↑ ledipasvir<br/>↑ simeprevir<br/>
</td>
<td stylecode="Rrule">Concentrations of ledipasvir and simeprevir are increased when simeprevir is coadministered with ledipasvir.  Coadministration of HARVONI with simeprevir is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Herbal Supplements:</content>
<br/>St. John's wort <content stylecode="italics">(Hypericum perforatum)</content>
</td>
<td stylecode="Rrule">↓ ledipasvir<br/>↓ sofosbuvir<br/>↓ GS-331007</td>
<td stylecode="Rrule">Coadministration of HARVONI with St. John's wort, a P-gp inducer is not recommended <content stylecode="italics">[see <linkhtml href="#S5.2">Warnings and Precautions (5.2)</linkhtml>].</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA Reductase Inhibitors:</content>
<br/>rosuvastatin</td>
<td stylecode="Rrule">↑ rosuvastatin<br/>
</td>
<td stylecode="Rrule">Coadministration of HARVONI with rosuvastatin may significantly increase the concentration of rosuvastatin which is associated with increased risk of myopathy, including rhabdomyolysis. Coadministration of HARVONI with rosuvastatin is not recommended.</td>
</tr>
</tbody>
</table>